Idhifa Enasidenib

Fact of Medicine

  • Brand Name: Idhifa
  • Innovator Brand Name: Idhifa
  • API: Enasidenib
  • Packaging: 30 Tablets
  • Strength: 50mg/100mg
  • Manufacturer Name: Agios Pharmaceuticals
Get Price
Categories: ,

Description

Uses of medication: Idhifa (Enasidenib) is used for the treatment of patients with AML with an IDH2 mutation whose disease has come back or has not improved following previous treatment.

Dosage: The recommended starting dose is idhifa 100mg, which should be administered orally once daily either with or without food about the same time each day. Don’t crush or split the idhifa tablets. If an idhifa dose is puked, missed, or not taken at the usual time, take the dose promptly on the same day, and back to the normal dosing schedule the following day.

Treatment Reactions: The most commonly reported enasidenib side effects include:

  • Nausea
  • Vomiting
  • Diarrhea
  • Elevated bilirubin
  • Decreased appetite

Warning and precautions

  • In patients with idhifa 100mg, if differentiation syndrome is suspected, start corticosteroid therapy and hemodynamic monitoring until the symptom resolution.
  • Blood counts, as well as blood chemistries for the leukocytosis and TLS, should be assessed prior to the initiation of enasidenib 50mg.
  • Use of idhifa is restricted in females of reproductive potential and males with female partners of reproductive potential.
  • Due to potential for adverse reactions in the breastfed infant, women should not breastfeed while on idhifa drug and for at least a couple of months following the last dose.

More Info.

Storage: Store Enasidenib at temperature 20°C to 25°C (68°F to 77°F); excursions permitted between temperature 15°C to 30°C (59°F to 86°F). Bottle should be kept tightly closed. Tablets should be stored in the original bottle (with a desiccant canister) in order to protect from moisture.

Availability in India: The Indian Pharma helps connect buyers with suppliers who can ship IDHIFA at the global level as per the need of buyer’s. The Indian Pharma provides guarantee of quality as well as delivery for the IDHIFA Tablets.

Buying Procedure: In order to buy IDHIFA, you can contact us at our Toll-free number 1800 889 1064 or on WhatsApp number +919650877511 or an Email to us at: info@theindianpharma.com along with your ID Proof, Valid Prescription Letter and Medical Reports.

Conclusion: The FDA approved enasidenib, when taken as a once-daily oral medication may provide appropriate patients with Acute myeloid leukemia a practical treatment option.

Commonly Asked Questions

What does Idhifa contain as an active substance?

The medication Idhifa specifically contains the active substance Enasidenib.

From which class of drug Enasidenib belongs?

Enasidenib basically belongs to a class of drugs named IDH2 inhibitors.

How does Enasidenib act?

Enasidenib acts in order to inhibit IDH2 and release the block on maturation of the young blood cells. Meaning that the young cells in the marrow may grow up to be generally functioning healthy RBCs, WBCs, and platelets. This also assists relieve overcrowding of the immature blood cells in the marrow.

How much does idhifa cost?

The idhifa price in India may vary depending on the wholesaler/pharmacy you visit. Cost for the idhifa oral tablet 50mg is around 2,123,856 INR for a supply of 30 tablets.

Where can I get Enasidenib at the best price?

In order to get the best enasidenib price, always buy this medication from a such Pharmaceutical Wholesaler Company which is ISO and WHO-GDP certified.

Can I get Enasidenib (Idhifa) even if I am not based in India?

The Indian Pharma helps patients in accessing or importing Enasidenib (Idhifa), not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.

Send your inquiry to find Idhifa (Enasidenib Tablets) in UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela, Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia, Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand. China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.

×